Today: 24 March 2026
Subscribe
Browse Category

Stock Market 2 January 2026

Booking Holdings stock falls today as Wall Street wobbles to start 2026 — what’s driving BKNG

Booking Holdings stock falls today as Wall Street wobbles to start 2026 — what’s driving BKNG

Booking Holdings fell 0.9% to $5,306.83 in afternoon trading Friday, tracking a broader pullback in U.S. consumer discretionary stocks as equities gave back early gains. Shares traded between $5,254 and $5,376.50 after opening at $5,356.79. Investors are watching next week’s U.S. labor data and interest rate signals. Regulatory scrutiny in Europe remains an overhang.
2 January 2026
·
Palo Alto Networks stock today: PANW slides nearly 3% as cybersecurity shares lag to start 2026

Palo Alto Networks stock today: PANW slides nearly 3% as cybersecurity shares lag to start 2026

Palo Alto Networks shares fell 2.9% to $178.87 in afternoon trading Friday, underperforming the S&P 500, which edged up 0.2%. CrowdStrike, Zscaler, and Fortinet also declined. About 4.1 million Palo Alto shares changed hands as traders awaited next week’s U.S. jobs and inflation data. The stock traded between $186.99 and $177.23 during the session.
2 January 2026
···
Texas Instruments (TXN) stock jumps nearly 3% as chip rally returns — what investors watch next

Texas Instruments (TXN) stock jumps nearly 3% as chip rally returns — what investors watch next

Texas Instruments shares rose 2.9% to $178.54 by 2:59 p.m. ET Friday, leading gains among chip stocks as the iShares Semiconductor ETF climbed 4.5%. The Philadelphia Semiconductor Index was up 3.5%. Investors are watching next week’s U.S. jobs and inflation data for signals on 2026 rate cuts. CEO Haviv Ilan will become board chairman in January, succeeding Rich Templeton.
2 January 2026
····
Western Digital stock jumps 8% today as AI storage names lead early 2026 trade

Western Digital stock jumps 8% today as AI storage names lead early 2026 trade

Western Digital jumped 8% to $186.30 Friday, leading gains in storage stocks as Sandisk surged 14% and Micron rose 10%. The rally followed a strong 2025 for Western Digital, now focused on hard disk drives after spinning off its flash unit last February. Investors are watching upcoming U.S. jobs and inflation data for signals on interest rates.
2 January 2026
····
Carvana stock slides nearly 5% in first 2026 session as CVNA lags used-car peers

Carvana stock slides nearly 5% in first 2026 session as CVNA lags used-car peers

Carvana shares fell about 5% to $401.17 in Friday afternoon trading, trailing the broader market as the S&P 500 ETF edged up 0.1%. The stock touched a low of $390.87 after a strong 2025 and recent S&P 500 inclusion. CarMax rose 1.5%, while other rivals were little changed. Investors are watching for next week’s U.S. jobs and inflation data, and Carvana’s earnings expected Feb. 18.
2 January 2026
·
JFrog stock sinks nearly 7% despite Barclays note on new Enterprise X price hike

JFrog stock sinks nearly 7% despite Barclays note on new Enterprise X price hike

JFrog shares fell 6.9% to $58.16 Friday after the company raised prices on its self-hosted Enterprise X tier by about 6% starting Jan. 1, according to Barclays. The drop tracked a broader slide in software stocks, with the iShares Expanded Tech-Software ETF down 2.8%. Investors are watching if the price hike affects renewals ahead of JFrog’s expected February earnings update.
2 January 2026
··
1 … 676 677 678 679 680 … 1,361

Stock Market Today

  • Neovacs ALNEV.PA Pre-market Drops 11%, Heavy Euronext Trading Highlights Volatility
    March 23, 2026, 8:44 PM EDT. Neovacs S.A. (ALNEV.PA) trades pre-market at €0.0008 on March 24, 2026, down 11.11% with unusually high volume of 35.2 million shares on Euronext, more than double average levels. The stock shows extreme volatility and liquidity risks, with large spreads and price swings expected. Neovacs' market cap stands at €381, but negative earnings and a low current ratio underscore operational challenges. Technical indicators confirm oversold conditions amid a strong downtrend from €130 yearly highs. The biotech firm's pipeline includes Phase IIb clinical work on systemic lupus and other programs, though no earnings updates since 2019 add uncertainty. Traders face execution costs and event risk linked to pending clinical milestones, as AI-driven analysis suggests a HOLD rating for the stock.
Go toTop